ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study

ReiThera's vaccine candidate GRAd-COV2 encodes the full-length spike protein of the SARS-CoV-2 coronavirus.

ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study

ReiThera S.R.L., a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, today announces that the first healthy volunteer has been dosed in a Phase 1 study of the Company's vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2). The Phase 1 study is being conducted in Italy at the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome and at the GB Rossi University Hospital in Verona.

ReiThera's vaccine candidate GRAd-COV2 encodes the full-length spike protein of the SARS-CoV-2 coronavirus. The vaccine technology is based on a novel, proprietary replication-defective gorilla adenoviral (GRAd) vector, which both induced a strong humoral and cellular immune response in preclinical studies and demonstrated a good safety profile. GRAd-COV2 is expected to induce strong immune responses based on low pre-existing immunity to the vector in humans.

Vaccines based on similar simian adenoviral vectors, such as Chimpanzee adenoviral vectors (ChAd), have been evaluated in Phase 1 and 2 clinical trials in other infectious diseases and proved to be safe and immunogenic with a single-dose vaccine.

The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers divided equally into two age cohorts: 18-55 years and 65-85 years. Each cohort will be divided into three study arms of 15 volunteers which will be administered one of three escalating doses of GRAd-COV2. Participants will be monitored over a 24-week period.

The primary objective of the study is to evaluate the safety and tolerability of GRAd-COV2, and to select a vaccine dose for further investigation in a Phase 2/3 trial. The secondary objective is to evaluate the vaccine's ability to induce immune responses (antibodies and T cells) against the novel SARS-CoV-2 coronavirus in volunteers. Interim safety and immunogenicity analysis are expected by mid-Q4 2020 which will guide dose selection for Phase 2/3 studies.

A larger international Phase 2/3 trial in countries where SARS-CoV-2 is still very active is planned to commence by the end of 2020, pending positive interim safety and immunogenicity results of the Phase 1 trial. 

The Phase 1 trial of GRAd-COV2 is being funded by the Italian Ministry of Scientific Research and the Lazio Region. The study is being run jointly by ReiThera and Lazzaro Spallanzani INMI using initial vaccine material manufactured at ReiThera's cGMP facility in Rome.
In parallel, ReiThera is working with LEUKOCARE in Germany to develop a thermostable GRAd-COV2 vaccine formulation and with Univercells in Belgium to develop a bespoke manufacturing process to enable rapid, large-scale production of the vaccine.

"This study is the first important step in the clinical development of our novel GRAd-COV2 vaccine against COVID-19,said ReiThera's Chief Technology Officer, Stefano Colloca. "We are proud to undertake this trial in Italy where the impact of COVID-19 has been felt particularly hard. The cutting-edge science behind our approach is backed by many years of pioneering research on adenoviral vector technologies with pre-clinical and clinical data generated with a single-dose vaccine in other serious infectious diseases demonstrating potent humoral and cellular immune responses. This feature makes our technology platform suitable for an outbreak situation such as COVID-19 and has clear advantages in terms of manufacturing and compliance."

"The launch of this Phase 1 trial demonstrates ReiThera's expertise and what can be done when stakeholders come together towards a common goal," said ReiThera's Chief Executive Officer, Antonella Folgori. "We are grateful to Lazzaro Spallanzani INMI for their ongoing collaboration and to the Italian Ministry of Scientific Research and the Lazio Region for funding the trial and initial manufacturing of the GRAd-COV2 vaccine candidateWe look forward to providing important updates about the safety and immunogenicity of our vaccine candidate over the coming months, and potentially advancing into international Phase 2/3 trial later in the year."

About GRAd-COV2

GRAd-COV2, the candidate vaccine against SARS-CoV-2 recently developed by ReiThera, is based on a novel and proprietary replication-defective simian (gorilla) adenoviral vector (called GRAd) encoding the full-length coronavirus spike protein (GRAd-COV2). The spike protein enables the coronavirus to enter human cells.

Simian adenoviral (SAd) vectors have been extensively used as delivery agents for genetic vaccine candidates against multiple infectious diseases, including Ebola and RSV (Respiratory Syncytial Virus), in different populations, with more than 5,000 individuals including elderly and infants enrolled in early and late-stage clinical trials to date. Preclinical and clinical evidence has demonstrated that ReiThera's vaccine technology is safe and induces robust cellular and humoral immune responses.

ReiThera's novel GRAd vector belongs to species C adenovirus that are considered the most potent vaccine carriers and have low seroprevalence in humans. This means that GRAd vaccine immunogenicity is not hampered by pre-existing anti-human adenovirus antibodies.

IndraStra Global is now available on
Apple NewsGoogle News, Flipboard, Feedburner, and Telegram
Name

-51,1,3D Technology,2,5G,8,Abkhazia,2,Academics,9,Accidents,19,Activism,1,ADB,12,ADIZ,1,Adults,1,Advertising,30,Advisory,2,Aerial Reconnaissance,11,Aerial Warfare,34,Aerospace,4,Afghanistan,83,Africa,109,Agile Methodology,2,Agriculture,15,Air Crash,9,Air Defence Identification Zone,1,Air Defense,5,Air Force,26,Air Pollution,1,Airbus,4,Aircraft Carriers,5,Aircraft Systems,1,Al Nusra,1,Al Qaida,4,Al Shabab,1,Alaska,1,ALBA,1,Albania,2,Algeria,3,American History,4,AmritaJash,10,Antarctic,1,Anthropology,7,Anti Narcotics,12,Anti Tank,1,Anti-Corruption,3,Anti-dumping,1,Anti-Piracy,2,Anti-Submarine,1,Anti-Terrorism Legislation,1,Antitrust,1,APEC,1,Apple,2,Applied Sciences,2,AQAP,2,Arab League,3,Architecture,1,Arctic,6,Argentina,7,Armenia,26,Army,3,Art,1,Artificial Intelligence,62,Arunachal Pradesh,1,ASEAN,10,Asia,64,Asia Pacific,22,Assassination,2,Asset Management,1,Astrophysics,2,ATGM,1,Atmospheric Science,1,Atomic.Atom,1,Augmented Reality,7,Australia,44,Austria,1,Automation,13,Automotive,124,Autonomous Flight,2,Autonomous Vehicle,2,Aviation,58,AWACS,1,Awards,17,Azerbaijan,14,Azeri,1,B2B,1,Bahrain,9,Balance of Payments,1,Balance of Trade,3,Balkan,10,Baltic,3,Baluchistan,8,Bangladesh,27,Banking,48,Bankruptcy,1,Basel,1,Bashar Al Asad,1,Bay of Bengal,5,BBC,1,Beijing,1,Belarus,3,Belgium,1,Belt Road Initiative,3,Beto O'Rourke,1,BFSI,1,Bhutan,9,Big Data,30,Big Tech,1,Bilateral Cooperation,13,BIMSTEC,1,Biography,1,Biotechnology,2,BISA,1,Bitcoin,7,Black Lives Matter,1,Black Money,2,Black Sea,1,Blockchain,31,Blood Diamonds,1,Bloomberg,1,Boeing,20,Boko Haram,7,Bolivia,6,Bomb,2,Bond Market,1,Book,10,Book Review,17,Border Conflicts,7,Border Control and Surveillance,5,Bosnia,1,Brand Management,14,Brazil,99,Brexit,22,BRI,5,BRICS,16,British,3,Broadcasting,16,Brunei,2,Brussels,1,Buddhism,1,Budget,3,Build Back Better,1,Bulgaria,1,Burma,2,Business & Economy,1004,C-UAS,1,California,5,Call for Proposals,1,Cambodia,6,Cameroon,1,Canada,46,Canadian Security Intelligence Service (CSIS),1,Carbon Economy,8,CAREC,1,Caribbean,9,CARICOM,1,Caspian Sea,2,Catalan,3,Caucasus,9,CBRN,1,Central African Republic,1,Central Asia,74,Central Asian,3,Central Eastern Europe,46,Certification,1,Chad,2,Chanakya,1,Charity,2,Chatbots,1,Chemicals,7,Child Labor,1,Children,4,Chile,10,China,455,Christianity,1,CIA,1,CIS,5,Citizenship,2,Civil Engineering,1,Civil Liberties,4,Civil Rights,2,Civil Society,4,Civilization,1,Clean Energy,4,Climate,62,Climate Change,15,Clinical Research,3,Clinton,1,Cloud Computing,40,Coal,4,Coast Guard,3,Cognitive Computing,12,Cold War,4,Colombia,15,Commodities,3,Communication,8,Communism,3,Compliance,1,Computers,40,Conferences,1,Conflict,80,Conflict Diamonds,1,Conflict Resolution,48,Conflict Resources,1,Congo,1,Construction,4,Consumer Behavior,4,Consumer Price Index,1,COP26,4,Coronavirus,106,Corporate Communication,1,Corporate Governance,4,Corporate Social Responsibility,4,Corruption,4,Costa Rica,2,Counter Intelligence,13,Counter Terrorism,80,COVID,5,COVID Vaccine,5,CPEC,8,CPG,3,Credit,1,Credit Score,1,Crimea,4,CRM,1,Croatia,2,Crypto Currency,12,Cryptography,1,CSTO,1,Cuba,6,Culture,4,Currency,6,Customer Relationship Management,1,Cyber Attack,6,Cyber Crime,2,Cyber Security & Warfare,104,Cybernetics,5,Cyberwarfare,16,Cyclone,1,Cyprus,5,Czech Republic,3,DACA,1,DARPA,3,Data,9,Data Analytics,35,Data Science,2,Database,2,Daughter.Leslee,1,Davos,1,DEA,1,DeBeers,1,Debt,11,Decision Support System,5,Defense,9,Defense Deals,5,Deforestation,2,Democracy,20,Democrats,2,Demonetization,6,Denmark. F-35,1,Denuclearization,1,Diamonds,1,Digital,38,Digital Economy,8,Digital Marketing,2,Digital Transformation,10,Diplomacy,10,Disaster Management,4,Disinformation,1,Diversity & Inclusion,1,Djibouti,2,Documentary,2,Doklam,1,Dokolam,1,Dominica,2,Donald Trump,42,Donetsk,2,Dossier,2,Drones,10,E-Government,2,E-International Relations,1,Earning Reports,2,Earth Science,1,Earthquake,5,East Africa,1,East China Sea,9,eBook,1,ECB,1,eCommerce,11,Econometrics,1,Economic Justice,1,Economics,39,Economy,76,ECOWAS,2,Ecuador,3,Edge Computing,2,Education,61,Egypt,24,Elections,29,Electric Vehicle,11,Electricity,5,Electronics,7,Emerging Markets,1,Employment,12,Energy,309,Energy Policy,28,Energy Politics,24,Engineering,23,England,2,Enterprise Software Solutions,8,Entrepreneurship,15,Environment,46,ePayments,12,Epidemic,6,ESA,1,Ethiopia,3,Eulogy,3,Eurasia,3,Euro,6,Europe,6,European Union,219,EuroZone,5,Exclusive,2,Exhibitions,2,Explosives,1,Export Import,3,F-35,5,Facebook,7,Fake News,3,Fallen,1,FARC,2,Farnborough. United Kingdom,2,FATF,1,FDI,5,Featured,1151,Fidel Castro,1,Fiji,1,Finance,17,Financial Markets,49,Financial Statement,2,Finland,5,Fintech,13,Fiscal Policy,12,Fishery,3,Food Security,22,Forces,1,Forecasting,1,Foreign Policy,12,Forex,2,France,26,Free Market,1,Free Syrian Army,4,Freedom,3,Freedom of Speech,1,FTC,1,Fujairah,97,Fund Management,1,Funding,22,Future,1,G20,6,G24,1,G7,3,Gaddafi,1,Gambia,2,Gaming,1,Garissa Attack,1,Gas Price,16,GATT,1,Gaza,2,GCC,11,GDP,9,GDPR,1,Geneal Management,1,General Management,1,Geo Politics,103,Geography,1,Geoint,14,Geopolitics,5,Georgia,11,Georgian,1,geospatial,8,Geothermal,2,Germany,60,Ghana,3,Gibratar,1,Gig economy,1,Global Trade,88,Global Warming,1,Global Water Crisis,10,Globalization,2,Gold,2,Google,13,Gorkhaland,1,Government,125,GPS,1,Greater Asia,126,Greece,13,Green Bonds,1,Greenland,1,Gross Domestic Product,1,GST,1,Gujarat,6,Gun Control,4,Hacking,4,Haiti,2,Hasan,1,Health,7,Healthcare,71,Heatwave,1,Helicopter,10,Heliport,1,Hezbollah,3,High Altitude Warfare,1,High Speed Railway System,1,Hillary 2016,1,Hillary Clinton,1,Hinduism,2,Hindutva,4,History,10,Home Security,1,Honduras,2,Hong Kong,7,Horn of Africa,5,Housing,11,Houthi,11,Howitzer,1,Human Development,28,Human Resource Management,5,Human Rights,4,Humanitarian,3,Hungary,3,Hunger,3,Hydrocarbon,3,Hydrogen,2,IAEA,2,ICBM,1,Iceland,1,ICO,1,Identification,2,IDF,1,Imaging,2,IMF,68,Immigration,17,Impeachment,1,Imran Khan,1,Independent Media,72,India,536,India's,1,Indian Air Force,18,Indian Army,5,Indian Nationalism,1,Indian Navy,24,Indian Ocean,16,Indices,1,Indo-Pacific,3,Indonesia,17,IndraStra,1,Industrial Accidents,3,Industrial Automation,2,Industrial Safety,4,Inflation,6,Infographic,1,Information Leaks,1,Infrastructure,3,Innovations,22,Insider Trading,1,Insurance,3,Intellectual Property,3,Intelligence,5,Intelligence Analysis,8,Interest Rate,3,International Business,13,International Law,11,International Relations,7,Internet,52,Internet of Things,34,Interview,8,Intra-Government,5,Investigative Journalism,3,Investment,32,Investor Relations,1,IPO,4,Iran,188,Iraq,54,IRGC,1,Iron & Steel,1,ISAF,1,ISIL,9,ISIS,33,Islam,12,Islamic Banking,1,Islamic State,86,Israel,119,IT ITeS,131,Italy,10,Jabhat al-Nusra,1,Jamaica,3,Japan,61,JASDF,1,Jihad,1,Joe Biden,3,Joint Strike Fighter,4,Jordan,7,Journalism,6,Judicial,4,Justice System,3,Kanchin,1,Kashmir,8,Kazakhstan,22,Kenya,5,Kiev,1,Kindle,700,Knowledge Management,3,Kosovo,2,Kurdistan,8,Kurds,10,Kuwait,7,Kyrgyzstan,9,Labor Laws,10,Labor Market,4,Land Reforms,2,Land Warfare,21,Languages,1,Laos,1,Laser Defense Systems,1,Latin America,79,Law,5,Leadership,3,Lebanon,9,Legal,9,LGBTQ,1,Liberalism,1,Library Science,1,Libya,13,Littoral Warfare,2,Livelihood,3,Loans,8,Lockdown,1,Lone Wolf Attacks,2,Lugansk,2,Macedonia,1,Machine Learning,7,Madagascar,1,Mahmoud,1,Main Battle Tank,3,Malaysia,10,Maldives,8,Mali,7,Malware,2,Management Consulting,6,Manpower,1,Manto,1,Manufacturing,14,Marijuana,1,Marine Engineering,3,Maritime,39,Market Research,2,Marketing,38,Mars,2,Martech,9,Mass Media,29,Mass Shooting,1,Material Science,2,Mauritania,1,MDGs,1,Mechatronics,2,Media War,1,Mediterranean,12,MENA,6,Mental Health,4,Mercosur,2,Mergers and Acquisitions,15,Meta,1,Metadata,2,Metals,1,Mexico,10,Micro-finance,4,Microsoft,11,Migration,19,Mike Pence,1,Military,99,Military Exercise,9,Military-Industrial Complex,1,Mining,15,Missile Launching Facilities,5,Missile Systems,51,Mobile Apps,3,Mobile Communications,10,Mobility,4,Modi,7,Moldova,1,Monaco,1,Monetary Policy,5,Money Market,2,Mongolia,8,Monkeypox,1,Monsoon,1,Montreux Convention,1,Moon,4,Morocco,1,Morsi,1,Mortgage,3,Moscow,2,Motivation,1,Mozambique,1,Mubarak,1,Multilateralism,2,Mumbai,1,Muslim Brotherhood,2,Myanmar,25,NAFTA,3,NAM,2,Nanotechnology,4,NASA,13,National Security,5,Nationalism,2,NATO,30,Natural Disasters,10,Natural Gas,29,Naval Base,5,Naval Engineering,19,Naval Intelligence,2,Naval Postgraduate School,2,Naval Warfare,44,Navigation,2,Navy,21,NBC Warfare,2,NDC,1,Negotiations,2,Nepal,12,Neurosciences,6,New Delhi,4,New Normal,1,New York,5,New Zealand,5,News,1055,Newspaper,1,NFT,1,NGO,1,Nicaragua,1,Niger,3,Nigeria,10,Nirbhaya,1,Non Aligned Movement,1,Non Government Organization,4,Nonproliferation,2,North Africa,22,North America,41,North Korea,48,Norway,2,NSA,1,NSG,2,Nuclear,38,Nuclear Agreement,30,Nuclear Doctrine,1,Nuclear Security,44,Obama,3,ObamaCare,2,OBOR,15,Ocean Engineering,1,Oceania,2,OECD,4,OFID,5,Oil & Gas,346,Oil Gas,6,Oil Price,56,Olympics,2,Oman,25,Omicron,1,Oncology,1,Online Education,5,Online Reputation Management,1,OPEC,122,Open Access,1,Open Journal Systems,1,Open Letter,1,Open Source,4,Operation Unified Protector,1,Operational Research,4,Opinion,611,Pacific,5,Pakistan,159,Pakistan Air Force,3,Pakistan Army,1,Pakistan Navy,3,Palestine,21,Palm Oil,1,Pandemic,84,Papal,1,Paper,3,Papers,110,Papua New Guinea,1,Paracels,1,Partition,1,Partnership,1,Passport,1,Patents,2,PATRIOT Act,1,Peace Deal,5,Peacekeeping Mission,1,Pension,1,People Management,1,Persian Gulf,19,Peru,5,Petrochemicals,1,Petroleum,19,Pharmaceuticals,13,Philippines,11,Philosophy,2,Photos,3,Physics,1,Pipelines,5,PLAN,3,Plastic Industry,2,Poland,7,Polar,1,Policing,1,Policy,7,Policy Brief,6,Political Studies,1,Politics,36,Polynesia,3,Population,3,Portugal,1,Poverty,5,Power Transmission,6,President APJ Abdul Kalam,2,Presidential Election,30,Press Release,158,Prison System,1,Privacy,17,Private Equity,1,Private Military Contractors,1,Programming,1,Project Management,4,Propaganda,5,Protests,11,Psychology,3,Public Policy,55,Public Relations,1,Public Safety,7,Publishing,6,Putin,4,Q&A,1,Qatar,101,QC/QA,1,Qods Force,1,Quantum Computing,3,Quantum Physics,4,Quarter Results,2,Racial Justice,2,RADAR,1,Rahul Guhathakurta,4,Railway,7,Raj,1,Ranking,4,Rape,1,RCEP,2,Real Estate,1,Recall,4,Recession,2,Red Sea,2,Referendum,5,Reforms,17,Refugee,23,Regional,4,Regulations,1,Rehabilitation,1,Religion & Spirituality,9,Renewable,13,Reports,38,Repository,1,Republicans,3,Rescue Operation,1,Research,4,Research and Development,20,Retail,36,Revenue Management,1,Risk Management,4,Robotics,8,Rohingya,5,Romania,2,Royal Canadian Air Force,1,Rupee,1,Russia,269,Russian Navy,5,Saab,1,Saadat,1,SAARC,6,Safety,1,SAFTA,1,SAM,2,Samoa,1,Sanctions,3,SAR,1,SAT,1,Satellite,12,Saudi Arabia,122,Scandinavia,6,Science & Technology,335,SCO,5,Scotland,6,Scud Missile,1,Sea Lanes of Communications,4,SEBI,1,Securities,1,Security,6,Semiconductor,3,Senate,4,Senegal,1,SEO,3,Serbia,4,Seychelles,1,SEZ,1,Shale Gas,4,Shanghai,1,Sharjah,12,Shia,6,Shinzo Abe,1,Shipping,5,Shutdown,1,Siachen,1,Sierra Leone,1,Signal Intelligence,1,Sikkim,4,Silicon Valley,1,Silk Route,6,Simulations,2,Sinai,1,Singapore,13,Situational Awareness,16,Smart Cities,7,Social Media Intelligence,40,Social Policy,39,Social Science,1,Socialism,1,Soft Power,1,Software,7,Solar Energy,11,Somalia,5,South Africa,18,South America,45,South Asia,405,South China Sea,31,South East Asia,61,South Korea,42,South Sudan,4,Sovereign Wealth Funds,1,Soviet,2,Soviet Union,7,Space,40,Space Station,2,Spain,8,Special Forces,1,Sports,2,Sports Diplomacy,1,Spratlys,1,Sri Lanka,22,Stamps,1,Startups,43,State of the Union,1,STEM,1,Stephen Harper,1,Stock Markets,18,Storm,2,Strategy Games,5,Sub-Sahara,3,Submarine,13,Sudan,5,Sunni,6,Super computing,1,Supply Chain Management,37,Surveillance,8,Survey,5,Sustainable Development,16,Swami Vivekananda,1,Sweden,3,Switzerland,3,Syria,111,Taiwan,20,Tajikistan,11,Taliban,17,Tamar Gas Fields,1,Tamil,1,Tanzania,4,Tariff,4,Taxation,23,Tech Fest,1,Technology,13,Tel-Aviv,1,Telecom,22,Telematics,1,Territorial Disputes,1,Terrorism,74,Testing,2,Texas,3,Thailand,7,The Middle East,606,Think Tank,290,Tibet,2,TikTok,1,Tobacco,1,Tonga,1,Total Quality Management,2,Town Planning,2,TPP,2,Trade Agreements,13,Trade War,9,Trademarks,1,Trainging and Development,1,Transcaucasus,16,Transcript,4,Transpacific,2,Transportation,39,Travel and Tourism,7,Tsar,1,Tunisia,7,Turkey,73,Turkmenistan,9,U.S. Air Force,3,U.S. Dollar,2,UAE,132,UAV,21,UCAV,1,Udwains,1,Uganda,1,Ukraine,94,Ukraine War,7,Ummah,1,UNCLOS,6,Unemployment,1,UNESCO,1,UNHCR,1,UNIDO,2,United Kingdom,69,United Nations,27,United States,654,University and Colleges,4,Uranium,2,Urban Planning,10,US Army,8,US Army Aviation,1,US Congress,1,US FDA,1,US Navy,15,US Postal Service,1,US Space Force,2,USA,16,USAF,19,UUV,1,Uyghur,3,Uzbekistan,12,Valuation,1,Vatican,1,Vedant,1,Venezuela,18,Venture Capital,3,Victim,1,Videogames,1,Vietnam,18,Virtual Reality,7,Vision 2030,1,VPN,1,Wahhabism,3,War,1,War Games,1,Warfare,1,Water,16,Water Politics,6,Weapons,10,Wearable,2,Weather,2,Webinar,1,WEF,2,Welfare,1,West,2,West Africa,19,West Bengal,2,Western Sahara,2,Whitepaper,2,WHO,3,Wikileaks,1,Wikipedia,1,Wildfire,1,Wildlife,2,Wind Energy,1,Windows,1,Wireless Security,1,Wisconsin,1,Women,10,Women's Right,10,Workshop,1,World Bank,27,World Economy,24,World Peace,10,World War I,1,World War II,3,WTO,6,Wyoming,1,Xi Jinping,9,Xinjiang,1,Yemen,26,Zbigniew Brzezinski,1,Zimbabwe,2,
ltr
item
IndraStra Global: ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study
ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study
ReiThera's vaccine candidate GRAd-COV2 encodes the full-length spike protein of the SARS-CoV-2 coronavirus.
https://1.bp.blogspot.com/-ibjjTwgRTNk/X0UFgR2BiII/AAAAAAAAFMI/7D5kNLNXRW4AbkmWL81wnQOu_Gr8TFwaQCLcBGAsYHQ/s640/AIDN0060820200043-CI.gif
https://1.bp.blogspot.com/-ibjjTwgRTNk/X0UFgR2BiII/AAAAAAAAFMI/7D5kNLNXRW4AbkmWL81wnQOu_Gr8TFwaQCLcBGAsYHQ/s72-c/AIDN0060820200043-CI.gif
IndraStra Global
https://www.indrastra.com/2020/08/ReiThera-s-COVID-19-Vaccine-Phase-1-Clinical-Study-006-08-2020-0043.html
https://www.indrastra.com/
https://www.indrastra.com/
https://www.indrastra.com/2020/08/ReiThera-s-COVID-19-Vaccine-Phase-1-Clinical-Study-006-08-2020-0043.html
true
1461303524738926686
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content